Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A male patient in his late sixties presents to the primary care clinic with a three-day history of dysuria, increased urinary frequency, and suprapubic discomfort. His past medical history is significant for a provoked deep vein thrombosis of the right lower extremity diagnosed three months ago, for which he has been receiving warfarin therapy. His International Normalized Ratio (INR) has been stable and therapeutic for the past six weeks. A point-of-care INR obtained today is 2.82.8. Urinalysis reveals positive leukocyte esterase, positive nitrites, and moderate bacteria. The physician diagnoses an uncomplicated urinary tract infection and decides to prescribe a three-day course of oral trimethoprim-sulfamethoxazole. Vital signs are within normal limits, and the patient is otherwise stable.

Which of the following is the most appropriate next step regarding this patient's anticoagulant management?

  1. A
    Continue the current warfarin dose and maintain the routine four-week interval for the next INR check
  2. B
    Measure an activated partial thromboplastin time (aPTT) prior to starting the antibiotic to establish a new baseline
  3. C
    Admit the patient to the hospital for continuous intravenous unfractionated heparin bridging during the antibiotic treatment
  4. Decrease the current warfarin dose by 25%25\% to 50%50\% and schedule an INR check in 33 to 55 daysCevap
  5. E
    Hold warfarin therapy for the duration of the antibiotic course to prevent the INR from exceeding the therapeutic range

Cevap

Decrease the current warfarin dose by 25%25\% to 50%50\% and schedule an INR check in 33 to 55 days.
Trimethoprim-sulfamethoxazole is a potent inhibitor of the cytochrome P450 2C9 (CYP2C9) isoenzyme. Warfarin is administered as a racemic mixture, and its more potent S-enantiomer is primarily metabolized by CYP2C9. When this antibiotic is introduced, warfarin metabolism is rapidly inhibited, leading to elevated serum levels and a supratherapeutic INR, which drastically increases the risk of major bleeding. The standard of care for a patient with a stable INR who must start a strong CYP2C9 inhibitor (such as trimethoprim-sulfamethoxazole, metronidazole, or fluconazole) is to pre-emptively reduce the weekly warfarin dose by 25%25\% to 50%50\% and to recheck the INR within 33 to 55 days. This approach ensures continuous therapeutic anticoagulation while proactively mitigating toxicity.

Adım Adım Çözüm

1
Identify the pharmacokinetic interaction between trimethoprim-sulfamethoxazole and warfarin.
Trimethoprim-sulfamethoxazole is a strong inhibitor of CYP2C9, the primary enzyme responsible for metabolizing the highly active S-enantiomer of warfarin.
Recognizing specific drug-drug interactions is required to anticipate their clinical effects on patient physiology.
2
Determine the expected clinical consequence of this specific drug-drug interaction.
Inhibition of warfarin metabolism will increase its serum concentration, leading to a supratherapeutic INR and a significantly elevated risk of bleeding.
Anticipating the adverse outcome dictates the necessity of a preventive intervention.
3
Select the appropriate clinical protocol for monitoring and treatment adjustment.
Empirical pre-emptive dose reduction of warfarin combined with early laboratory reassessment is the standard of care.
This strategy safely balances the need for continuous therapeutic anticoagulation against the imminent risk of drug-induced toxicity.

Anahtar Kavram

Empiric dose reduction and close INR monitoring when initiating strong CYP2C9 inhibitors in patients on warfarin.
Tahmini Süre:1m 0s
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru